Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Replimune Group, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2019
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Research and development
6.94
13.5
22.2
38.8
56.8
79.5
127
175
189
221
Selling, general and administrative
72.2
98.7
General and administrative
2.71
5.71
8.77
17.4
23.2
38.8
50.6
59.8
72.2
Operating expenses
9.65
19.2
30.9
56.2
80
118
177
235
262
320
Operating income
-9.65
-19.2
-30.9
-56.2
-80
-118
-177
-235
-262
-320
Interest expense
0.73
0.82
0
1.96
4.5
5.78
6.8
Interest income
0.03
0.29
2.59
2.42
0.92
0.39
10
23.4
21.1
13.6
Other non-operating income
1.94
-0.47
0.11
3.57
-0.92
0.28
3.08
19.4
14.8
5.43
Pre-tax income
-7.7
-19.7
-30.8
-52.6
-80.9
-118
-174
-215
-247
-314
Income tax
0
0
0
0
0
0
0.29
0.41
0.47
-0.55
Income from continuing operations
-80.9
-118
-174
-215
-247
-314
Net income
-7.7
-19.7
-30.8
-52.6
-80.9
-118
-174
-216
-247
-314
EBITDA
-9.53
-19.1
-30.8
-55.7
-78.2
-116
-175
-232
-258
-317
EPS, basic
-1.55
-3.96
-1.33
-1.54
-1.75
-2.26
-2.99
-3.24
-3.07
-3.38
EPS, diluted
-1.55
-3.96
-1.33
-1.54
-1.75
-2.26
-2.99
-3.24
-3.07
-3.38
Shares, basic (weighted)
4.97
4.98
23.2
34.3
46.2
52.2
58.2
66.6
80.6
92.8
Shares, diluted (weighted)
4.97
4.98
23.2
34.3
46.2
52.2
58.2
66.6
80.6
92.8
Balance sheet
FY2017
FY2019
FY2019
FY2019
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
20.7
17.6
25.7
59.5
183
106
147
74.5
111
209
Short-term investments
44
109
109
294
290
437
346
373
59.9
Other current assets
0.76
3.7
2.73
4.49
5.27
6.28
8.08
8.35
8.61
Total current assets
64.7
141
174
484
404
593
434
496
279
Property, plant and equipment
0.37
12.2
6.86
7.44
7.93
7.48
10.5
13.7
13
Lease right-of-use assets
4.43
5.75
5.55
5.21
4.64
4
3.27
Other non-current assets
0
1.2
2.94
Total assets
65.2
154
234
543
461
647
488
551
332
Accounts payable
1.99
7.08
3.43
2.36
3.73
5.36
2.58
12.5
6.67
Total current liabilities
5.16
9.89
11.9
14.5
20.8
33.8
40.4
62.4
58.2
Long-term debt
0
28.6
44.8
46.4
83.3
Lease liabilities
3.74
5.08
4.8
4.39
3.77
3.08
2.33
Other non-current liabilities
0
0.47
0.79
0.94
0.46
Total liabilities
6.86
16.5
50.4
44.4
50
91.3
113
135
166
Total debt
9.8
0
28.6
44.8
46.4
83.3
Paid-in capital
1.1
199
297
692
723
1,035
1,071
1,359
1,423
Retained earnings
-28.9
-59.8
-112
-193
-311
-485
-701
-949
-1,263
Other comprehensive income
-0.24
-1.06
-0.98
-0.39
-0.97
5.73
4.86
5.45
5.4
Shareholders' equity
-11.5
-28.1
138
184
499
411
555
375
416
166
Total equity
-11.5
-28.1
138
184
499
411
555
375
416
166
Total liabilities and equity
65.2
154
234
543
461
647
488
551
332
Shares outstanding
5.01
31.7
36.7
46.6
47.3
56.7
61.4
77.1
82.7
Cash flow statement
FY2017
FY2019
FY2019
FY2019
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
7.7
-19.7
-30.8
-52.6
-80.9
-118
-174
-216
-247
-314
Depreciation and amortization
0.12
0.11
0.15
0.53
1.71
2.15
2.45
2.66
3.5
3.33
Stock-based compensation
0.21
0.81
2.73
7.74
11.8
24.3
28.1
34.1
35
32.3
Change in payables
0.2
1.6
0.12
-3.82
-1.03
1.12
1.98
-2.79
9.94
-4.94
Cash from operations
-7.08
-16
-25.4
-60.6
-61.4
-82.2
-128
-185
-192
-280
Capital expenditures
-0.24
-0.14
-2.6
-6.54
-2.39
-2.34
-2.27
-5.66
-6.69
-4.22
Purchases of investments
-52.5
-190
-150
-392
-256
-583
-490
-404
-77.9
Cash from investing
-0.24
-44
-65.9
-5.23
-189
-1.81
-143
97.2
-23.8
311
Debt issued
10
0
28.2
15
0
35
Debt repaid
-10
0
Stock issued
0.21
0.55
286
0
150
0
156
0.88
Cash from financing
15
54.8
101
100
372
6.6
311
16.3
252
66.3
Exchange rate effect
-1.42
2.3
-0.84
-0.14
0.72
0.82
-0.11
-0.09
0.32
1.11
Net change in cash
6.27
-3.01
9.23
34.2
123
-76.6
40.6
-72.1
36.7
97.9
Free cash flow
-7.32
-16.2
-28
-67.1
-63.8
-84.5
-130
-191
-199
-285
Interest paid
0.58
0.64
0
1.07
3.04
4.2
4.69
Income taxes paid
0
0.06
0
0.3
0.11
-0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $12.36 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-281.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-117.7%
Net income / average total assets.
Return on invested capital (ROIC)
-5,346.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-60.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-33.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-19.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-39.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-19.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-9.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
15.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
16.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
14.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.23x
Current assets / current liabilities.
Quick ratio
5.09x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
5.09x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.80x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
33.3%
Total debt / total assets.
Liabilities / assets
58.2%
Total liabilities / total assets.
Net debt
-$111.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$2.90
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.88
Cash from operations / diluted weighted shares.
Book value per share
$1.26
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
11.0x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
11.0x
Market cap / tangible book value, when positive.
FCF yield
-24.1%
Free cash flow / market cap.
Earnings yield
-25.5%
Net income / market cap (the inverse of P/E).
Was Replimune Group, Inc. profitable in fiscal 2026?
No. It reported a net loss of $313.9M.
How much free cash flow did Replimune Group, Inc. generate in fiscal 2026?
Cash from operations of $280.3M minus capital expenditures of $4.2M left free cash flow of -$284.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.